Earnings summaries and quarterly performance for Immunome.
Executive leadership at Immunome.
Clay Siegall
Detailed
President and Chief Executive Officer
CEO
BL
Bob Lechleider
Detailed
Chief Medical Officer
JH
Jack Higgins
Detailed
Chief Scientific Officer
KH
Kinney Horn
Detailed
Chief Business Officer
MR
Max Rosett
Detailed
Chief Financial Officer
PT
Phil Tsai
Detailed
Chief Technical Officer
RS
Roee Shahar
Detailed
Executive Vice President, Commercial
SS
Sandra Stoneman
Detailed
Chief Legal Officer and General Counsel
Board of directors at Immunome.
Research analysts covering Immunome.
Recent press releases and 8-K filings for IMNM.
Immunome Announces Pricing of Public Offering of Common Stock
IMNM
- Immunome, Inc. (IMNM) priced an underwritten public offering of 18,625,000 shares of its common stock at $21.50 per share.
- The offering is expected to generate approximately $400 million in gross proceeds for Immunome.
- Underwriters have a 30-day option to purchase up to an additional 2,793,750 shares of common stock.
- The offering is anticipated to close on December 18, 2025.
Dec 17, 2025, 1:16 AM
Immunome Announces Proposed Public Offering of Common Stock
IMNM
- Immunome, Inc. announced a proposed underwritten public offering to issue and sell $400 million of its common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock.
- The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
- Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Dec 15, 2025, 9:01 PM
Immunome announces positive Phase 3 Ringside trial results for AL102 in desmoid tumors
IMNM
Product Launch
New Projects/Investments
- Immunome reported positive top-line results from its Ringside phase 3 study of AL102 for desmoid tumors, with the trial meeting all primary and secondary endpoints.
- Key efficacy data for AL102 include a progression-free survival (PFS) hazard ratio of 0.16, an objective response rate (ORR) of 56%, and a median best tumor volume reduction of 83%.
- AL102, an oral gamma secretase inhibitor, demonstrated a manageable safety profile consistent with its drug class and is positioned as a potential best-in-class treatment.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026.
- The company is advancing commercial preparations to target the approximately 11,000 actively managed desmoid tumor patients in the U.S..
Dec 15, 2025, 1:30 PM
Immunome Announces Positive Phase 3 Results for Varegacestat in Desmoid Tumors
IMNM
Product Launch
New Projects/Investments
- Immunome reported positive top-line results from its Phase 3 Ringside trial for varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors, meeting all primary and secondary endpoints.
- Key efficacy outcomes include a progression-free survival (PFS) hazard ratio of 0.16 (representing an 84% reduction in disease progression risk), a confirmed objective response rate (ORR) of 56%, and a median best percentage reduction of tumor volume of 83%.
- Varegacestat was generally well tolerated with a manageable safety profile, showing a 55.6% ovarian toxicity rate in women of childbearing potential, which is lower than the up to 75% reported for the GSI class.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026, with commercial preparations on track for launch.
Dec 15, 2025, 1:30 PM
Immunome Announces Positive Phase 3 Ringside Trial Results for AL102
IMNM
Product Launch
New Projects/Investments
- Immunome's AL102 met all primary and secondary endpoints in the Phase 3 Ringside trial for progressing desmoid tumors, demonstrating a 0.16 progression-free survival (PFS) hazard ratio, a 56% confirmed objective response rate (ORR), and an 83% median best percentage reduction of tumor volume.
- AL102 was generally well tolerated with a manageable safety profile consistent with the GSI class, with common adverse events including diarrhea, fatigue, rash, nausea, and cough, mostly grade one or two.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026.
- The company aims to establish AL102 as the standard of care for desmoid tumors, focusing commercial efforts on approximately 85 specialty sarcoma centers in the U.S. and expecting greater than 90% payer coverage at launch.
Dec 15, 2025, 1:30 PM
IMNM Announces Positive Topline Results for Varegacestat Phase 3 RINGSIDE Study
IMNM
Product Launch
New Projects/Investments
- IMNM's Varegacestat achieved its primary and all key secondary endpoints in the RINGSIDE Phase 3 study for Desmoid Tumors, demonstrating a Progression-Free Survival hazard ratio of 0.16 (p<0.0001) and a 56% Confirmed Objective Response Rate.
- The study showed an 84% reduction in the risk of progression or death versus placebo and a median best tumor volume reduction of 83% with Varegacestat.
- Varegacestat was generally well-tolerated with a manageable safety profile, although 55.6% of premenopausal women experienced ovarian toxicity.
- An NDA submission for Varegacestat is planned for 2Q 2026, with the company positioning it to become the Standard of Care in Desmoid Tumors due to its best-in-class results.
Dec 15, 2025, 1:30 PM
Immunome Announces Positive Phase 3 Results for Varegacestat and Plans Q2 2026 NDA Submission
IMNM
Product Launch
New Projects/Investments
- Immunome, Inc. announced positive topline results from its global pivotal Phase 3 RINGSIDE trial of varegacestat for desmoid tumors on December 15, 2025.
- The trial met its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death (hazard ratio = 0.16, p<0.0001) and a confirmed objective response rate of 56% with varegacestat versus 9% with placebo.
- Varegacestat was generally well tolerated with a manageable safety profile, and Immunome plans to submit a New Drug Application to the U.S. FDA in Q2 2026.
Dec 15, 2025, 12:05 PM
Immunome Announces Positive Phase 3 RINGSIDE Trial Results for Varegacestat
IMNM
Product Launch
New Projects/Investments
- Immunome announced positive topline results from its global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors.
- The trial met its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death (hazard ratio = 0.16, p<0.0001) for varegacestat compared to placebo.
- All key secondary endpoints were also met, with varegacestat delivering an objective response rate of 56% versus 9% with placebo.
- Varegacestat was generally well tolerated with a manageable safety profile.
- Based on these data, Immunome plans to submit a New Drug Application to the U.S. FDA in Q2 2026.
Dec 15, 2025, 12:00 PM
Immunome to Announce Topline Results for Phase 3 RINGSIDE Trial
IMNM
New Projects/Investments
- Immunome, Inc. (Nasdaq: IMNM) is scheduled to announce topline results from its global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors.
- The announcement will take place on Monday, December 15, 2025, at 8:30 a.m. ET via a webcast and conference call.
- Varegacestat is an investigational, oral, once-daily gamma secretase inhibitor.
Dec 14, 2025, 9:00 PM
Immunome Discusses 2025 Achievements and 2026 Pipeline Outlook
IMNM
Guidance Update
New Projects/Investments
Product Launch
- Immunome anticipates top-line data for AL102 in desmoid tumors by the end of 2025, with prior Phase 2 data indicating a 64% objective response rate and 88% median tumor volume reduction, which the company believes is superior to Ogsiveo's 41% ORR and 59% reduction.
- The company filed an IND for its lead ADC, IM1021 (targeting ROR1), at the end of 2024, has observed initial activity, and anticipates sharing a more comprehensive data set at a conference in 2026.
- Immunome's ADC platform, featuring the HC-74 topo I inhibitor payload, aims to overcome resistance and offers a broader therapeutic index, allowing for a better safety profile compared to competitor technologies.
- Looking ahead to 2026, Immunome plans to file multiple additional INDs for other ADCs, including IM-1617, IM-1340, and IM-1335, all with solid tumor potential.
Dec 3, 2025, 2:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more